Vol. 2 No. 7 (2022)
Reimbursement Reviews

Selpercatinib (Retevmo)

Published July 13, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses selpercatinib (Retevmo), 40 mg and 80 mg, capsules, oral.
  • Indication: As monotherapy for the treatment of metastatic RET fusion–positive non–small cell lung cancer in adult patients.